Advanced search
Publication Cover
Acta Oncologica Volume 46, 2007 - Issue 3
Journal homepage
636
Views
7
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLE

Phase I study of short-time oxaliplatin, capecitabine and epirubicin (EXE) as first line therapy in patients with non-resectable gastric cancer

Jeanette Dupont Department of Oncology, Odense University Hospital, Odense, DenmarkCorrespondence[email protected]
,
Helle A. Jensen Department of Oncology, Odense University Hospital, Odense, Denmark
,
Benny V. Jensen Department of Oncology, Herlev Hospital, Copenhagen, Denmark
&
Per Pfeiffer Department of Oncology, Odense University Hospital, Odense, Denmark
Pages 330-335 | Received 26 May 2006, Published online: 08 Jul 2009

Citations (7)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Maria Andersen, Katrine R. Schønnemann, Mette Yilmaz, Helle A. Jensen, Lene W. Vestermark & Per Pfeiffer. (2010) Phase I study of docetaxel, oxaliplatin and capecitabine (TEX) as first line therapy to patients with advanced gastro-oesophageal cancer. Acta Oncologica 49:8, pages 1246-1252.
Read now
Olav Dahl. (2009) Follow up your unexpected clinical observations!. Acta Oncologica 48:3, pages 325-327.
Read now
Alicia Okines, Ian Chau & David Cunningham. (2007) Capecitabine in advanced gastric cancer. Expert Opinion on Pharmacotherapy 8:16, pages 2851-2861.
Read now

Articles from other publishers (4)

Per Pfeiffer & Camilla Qvortrup. 2021. Multidisciplinary Treatment of Colorectal Cancer. Multidisciplinary Treatment of Colorectal Cancer 187 202 .
Per Pfeiffer, Camilla Qvortrup & Josep Tabernero. 2015. Multidisciplinary Treatment of Colorectal Cancer. Multidisciplinary Treatment of Colorectal Cancer 109 132 .
J. Aubrey Waddell & Dominic A. SolimandoJrJr. (2011) Epirubicin, Oxaliplatin, and Capecitabine Regimen for Gastric and Esophageal Cancer. Hospital Pharmacy 46:9, pages 657-663.
Crossref
K R Schønnemann, H A Jensen, M Yilmaz, B V Jensen, O Larsen & P Pfeiffer. (2008) Phase II study of short-time oxaliplatin, capecitabine and epirubicin (EXE) as first-line therapy in patients with non-resectable gastric cancer. British Journal of Cancer 99:6, pages 858-861.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.